These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 19876042)

  • 1. Targeting protein kinases in central nervous system disorders.
    Chico LK; Van Eldik LJ; Watterson DM
    Nat Rev Drug Discov; 2009 Nov; 8(11):892-909. PubMed ID: 19876042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
    Amigoni F; Legnaghi E; Pevarello P
    Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
    Nienaber V
    Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for delivering therapeutics across the blood-brain barrier.
    Terstappen GC; Meyer AH; Bell RD; Zhang W
    Nat Rev Drug Discov; 2021 May; 20(5):362-383. PubMed ID: 33649582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of targeted therapies for central nervous system metastases.
    Pfeil AJ; Hale JD; Zhang TS; Wakayama K; Miyazaki I; Odintsov I; Somwar R
    Dis Model Mech; 2024 Sep; 17(9):. PubMed ID: 39344915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
    Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
    CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The aquaporin-4 water channel as a potential drug target in neurological disorders.
    Verkman AS; Smith AJ; Phuan PW; Tradtrantip L; Anderson MO
    Expert Opin Ther Targets; 2017 Dec; 21(12):1161-1170. PubMed ID: 29072508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
    Crawford L; Rosch J; Putnam D
    J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS drug delivery systems: novel approaches.
    Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoemulsions in CNS drug delivery: recent developments, impacts and challenges.
    Karami Z; Saghatchi Zanjani MR; Hamidi M
    Drug Discov Today; 2019 May; 24(5):1104-1115. PubMed ID: 30914298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles-based delivery system and its potentials in treating central nervous system disorders.
    Liu T; Xie Q; Dong Z; Peng Q
    Nanotechnology; 2022 Aug; 33(45):. PubMed ID: 35917704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic modalities to address nondrugable protein interaction targets.
    De Souza EB; Cload ST; Pendergrast PS; Sah DW
    Neuropsychopharmacology; 2009 Jan; 34(1):142-58. PubMed ID: 18754007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary delivery of therapeutic compounds for treating CNS disorders.
    Noymer P; Biondi S; Myers D; Cassella J
    Ther Deliv; 2011 Sep; 2(9):1125-40. PubMed ID: 22833910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.
    Patel MM; Patel BM
    CNS Drugs; 2017 Feb; 31(2):109-133. PubMed ID: 28101766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.
    Vuillemenot BR; Korte S; Wright TL; Adams EL; Boyd RB; Butt MT
    Toxicol Sci; 2016 Jul; 152(1):3-9. PubMed ID: 27354708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNS delivery of targeted protein degraders.
    Agarwal P; Reid DL; Amiji M
    J Control Release; 2024 Aug; 372():661-673. PubMed ID: 38936742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
    Sarin H
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.